Dean Heller sold Medtronic PLC (NYSE: MDT)
Dean Heller (R-NV), a U.S. Senator, has disclosed 1 trade in Medtronic PLC (MDT) since 2018, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Dean Heller sold $1,001 - $15,000 of Medtronic PLC (NYSE: MDT) on June 11, 2018. Since that trade, MDT is up +25.77% against the S&P 500 up +196.34%, an outperformance of -170.57%.
Data updated
Dean Heller's MDT trades vs the price
MDT is up +25.77% since Dean Heller sold on June 11, 2018, versus +196.34% for the S&P 500.
Performance since this trade
All Dean Heller MDT trades
Dean Heller & MDT trading FAQ
Is it legal for Dean Heller to trade Medtronic PLC (MDT) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Medtronic PLC (MDT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Dean Heller sell MDT?
Dean Heller disclosed a sale of $1,001 - $15,000 of Medtronic PLC (MDT) on June 11, 2018, according to public STOCK Act filings.
How has MDT performed since Dean Heller's trade?
Since Dean Heller sold MDT on June 11, 2018, the stock is up +25.77%, versus +196.34% for the S&P 500 over the same period, an outperformance of -170.57%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MDT trades?
Quantellect tracks every disclosed congressional trade in Medtronic PLC (MDT) on the Medtronic PLC congressional trading page, which aggregates filings across all members of Congress.
Dean Heller's MDT tradesAll congressional filings for Medtronic PLCDean Heller's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.